From Cannabis Receptors to Clinical Response: The State of CBD for Epilepsy | Research

The takeaway

CBD shows anticonvulsant potential through multiple pharmacological mechanisms, and high-CBD/low-THC products are becoming available, but rigorous clinical trial data is still needed.

Read this if you want to understand the science behind CBD for epilepsy.

CBD has polypharmacological action; mechanism differs from THC's direct CB1 activation

What the researchers found

The review covers three key areas. First, recreational cannabis use is widespread among adults with epilepsy, and medicinal use is growing with changing legal environments. High-CBD/low-THC products have become more available.

Second, while THC acts primarily through CB1 receptors, CBD's mechanism of action is less clear and likely involves multiple pharmacological targets (polypharmacological). There is anecdotal evidence of efficacy and discussion of a potential "entourage effect" between CBD and THC.

Third, the endocannabinoid system plays a clear role in seizure generation, maintenance, and control in animal models. While cannabis has documented negative effects on the developing and mature brain, these effects appear relatively mild in most cases. The authors call for well-designed studies on both short- and long-term efficacy and safety of CBD products for seizures.

Why it matters

This review was published at a critical juncture when families were already using CBD products for epilepsy (following Charlotte's Web publicity) but before any controlled clinical trials had been completed. It frames the scientific questions that needed to be answered before CBD could be considered a legitimate epilepsy treatment.

The numbers in context

THC acts via CB1 receptors. CBD has polypharmacological action. Endocannabinoid system shown to regulate seizures in animal models. Brain effects of cannabis described as "relatively mild in most cases."

How the study worked

This is a narrative review covering cannabinoid pharmacology, endocannabinoid system involvement in epilepsy, preclinical and anecdotal clinical evidence for CBD in seizure control, and known adverse effects of cannabis on the brain.

What this study cannot tell us

The review was written before controlled clinical trial data became available. Much of the evidence was preclinical or anecdotal. The characterization of cannabis brain effects as "relatively mild" may understate risks for certain populations. The review does not provide quantitative analysis of efficacy data.

How to read the evidence

This is a narrative review of primarily preclinical and anecdotal evidence, published before controlled clinical trials were completed.

When this study was published

Published in 2014. Epidiolex (pharmaceutical CBD) was FDA-approved for Dravet and Lennox-Gastaut syndromes in 2018 based on subsequent RCTs.

The bigger picture

This review captures the state of knowledge before the landmark clinical trials that led to Epidiolex (pure CBD) approval in 2018. It lays out the scientific rationale that justified those trials while acknowledging that the evidence at the time was primarily preclinical and anecdotal.

Questions still open

Is CBD alone sufficient or is the entourage effect with other cannabinoids important? What are the optimal doses for seizure control? Are there specific epilepsy types that respond better to CBD?

Common questions

What is the entourage effect?

It is the theory that the full spectrum of compounds in cannabis (cannabinoids, terpenes, flavonoids) work together synergistically, producing effects greater than any single compound alone. Some researchers believe whole-plant extracts may be more effective than pure CBD for this reason.

Why is CBD polypharmacological?

Unlike THC, which primarily acts through CB1 receptors, CBD interacts with multiple molecular targets including serotonin receptors, TRP channels, GPR55, and others. This multi-target activity may explain its broad therapeutic potential but also makes its mechanism harder to characterize precisely.

Read the original research

Cannabis, cannabidiol, and epilepsy--from receptors to clinical response.

Epilepsy & behavior : E&B, 41, 277-82

View on PubMed ↗Publisher’s paper ↗

Citation

Szaflarski, Jerzy P; Bebin, E Martina. (2014). Cannabis, cannabidiol, and epilepsy--from receptors to clinical response.. Epilepsy & behavior : E&B, 41, 277-82. https://doi.org/10.1016/j.yebeh.2014.08.135